JADE101 is a monoclonal antibody designed to inhibit APRIL, a protein involved in IgA nephropathy, a chronic kidney disease caused by inflammation and damage.
Jade’s focus is to develop transformational, disease-modifying therapies targeting autoimmune diseases. The company’s lead candidate, JADE101, is a potentially best-in-class monoclonal antibody designed to inhibit the cytokine APRIL (A PRoliferation Inducing Ligand). Jade’s pipeline also includes JADE201, an anti-BAFF-R (B-cell activating factor receptor), and JADE301, an anti-IFN-β monoclonal antibody.
Jade Biosciences’ Board of Directors includes industry veterans in science, business, and strategy. The company secured financing to accelerate clinical development of its therapies.
Amy Sullivan manages development operations at Jade Biosciences, with nearly three decades of experience delivering clinical programs from early development through post-approval.
Eric led Chinook Therapeutics as President and CEO, guiding its acquisition by Novartis in 2023 for up to $3.5 billion. He has over 20 years of experience in biotechnology as an executive and board member.
Mr. Quick oversees finance, accounting, and treasury at Jade Biosciences as Senior Vice President of Finance. He previously led financial operations at Myeloid Therapeutics.
Dr. Klein serves as Chief Executive Officer and Board member of Oruka Therapeutics. Previously, he was a Partner at Versant Ventures, investing in early-stage biotechnology companies, and a member of the CRISPR Therapeutics leadership team.
